Glucagon, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-Glucagon, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Glucagon, Human |
| Clone | REAL1173 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Glucagon Antibody, anti-human, PE, REAdye_lease™. Clone REAL1173 is an antibody fragment derived from the full Glucagon antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1173 recognizes human Glucagon, also known as GCG, which is predominantly secreted from the alpha cells of the pancreas. Glucogon is cleaved into 8 chains and plays a key role in glucose metabolism and homeostasis. Glucagon is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin, and somatostatin. It raises plasma glucose levels in response to insulin-induced hypoglycemia and therfore is important in initiating and maintaining hyperglycemic conditions in diabetes. Used to treat severe hypoglycemia in insulin-dependent diabetics. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | |
| Immunogen | n/a |
| Other Names | GCG, Pro-glucagon, Glucagon-like peptide, GLP-1, GLP-2, Glicentin, GRPP, OXM, OXY |
| Gene, Accession # | n/a |
| Catalog # | 130-128-926 |
| Price | $460 |
| Order / More Info | Glucagon, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Kulina, G. R. et al. (2016) THE ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY AND MANAGEMENT OF DIABETES. Endocr Pract. 22 (5): 612-621. | Chabenne, J. R. et al. (2020) Structural Refinement of Glucagon for Therapeutic Use. J. Med. Chem. 663 (7): 3447-3460. | Janah, L. et al. (2019) Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20 (13): 3314. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies